Keywords
atrial fibrillation
coronary artery disease
How to Cite
Abstract
The aim: To estimate gut microbiota composition peculiarities in patients with coronary artery disease (CAD) and atrial fibrillation (AF) and to evaluate their connections with known cardiometabolic risk factors (CRF).
Materials and methods: 300 patients formed 3 groups: I group – 149 CAD patients without rhythm disorders, II group – 124 patients with CAD and AF paroxysm and control group (CG) – 27 patients without CAD and arrhythmias. 16-S rRNA sequencing checked gut microbiota composition. CRF which was explored are total cholesterol (TC), triglycerides (TG), low density lipoproteins (LDL), high density lipoproteins (HDL), lipoprotein α (Lpα), apolipoprotein A1 (ApoA1), apolipoprotein B (ApoB), C-reactive protein (CRP), interleukin-6 (IL-6), trymetilamine (TMA) and trymetilamine-N-oxide (TMAO).
Results: The significant changes of gut microbiota composition were found in CAD patients with AF paroxysm in comparison with CAD patients without arrythmia as increasing Actinomycetota phulum (P<0.05); increasing Actinobacter Spp. and decreasing Blautia Spp., Roseburia Inulinivorans, Bacteroides Thetaiotaomicron (P<0.05). Moreover, Actinobacter Spp., Akkermansia Muciniphila, Streptococcus Spp., Bacteroides Thetaiotaomicron, Bifidobacterium Spp. have the highest amount of significant correlations with CRF (body mass index, LDL levels; P<0.05). By the ROC-analysis we found the acceptable role of Lactobacillus Spp., Bifidobacterium Spp., Bacteroides Thetaiotaomicron, Blautia Spp., Actinobacter Spp. and Eubacterium Rectale in AF paroxysm occurrence in CAD patients (area under ROC-curve (AUC)<0.7). We found gut microbiota combinations with highest AUC for AF paroxysm in CAD patient: all of them include Actinobacter Spp (Actinobacter Spp. + 0.32 * Streptococcus Spp., AUC = 0.9008; 1.56 * Actinobacter Spp. – Blautia Spp., AUC = 0.9008;1.84 * Actinobacter Spp. – Akkermansia Muciniphila, AUC = 0.9008). AF paroxysm duration in CAD patients depends of plasma IL-6, TMAO, fecal Actinobacter Spp. and Akkermansia Muciniphila by the linear multifactorial regression analysis (AF paroxysm duration = 0.68*(Actinobacter Spp., lg/CFU/ml) – 3.33*(Akkermansia Muciniphila, lg/CFU/ml) – 0.6*IL6 – 0.34*TMAO – 0.98).
Conclusions: Gut microbiota condition is closely connected with occurrence AF of paroxysm in CAD patients. To find out the new ways of gut microbiota and CRF correction will be interesting in future investigations.
References
Hindricks, G, Potpara, T, Dagres, N, Arbelo, E, Bax JJ, Blomstrom-Lundqvist C, et all. (2020) ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal, 42,373498. doi:10.1093/eurheartj/ehaa612
Knuuti, J, Wijns, W, Saraste, A, Capodanno, D, Barbato, E, Funck-Brentano, C, et all. (2019) ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal, 41,407477. doi:10.1093/eurheartj/ehz425
Michniewicz, E., Mlodawska, E., Lopatowska, P., Tomaszuk-Kazberuk, A., & Malyszko, J. (2018). Patients with atrial fibrillation and coronary artery disease - Double trouble. Advances in medical sciences, 63(1), 30–35. https://doi.org/10.1016/j.advms.2017.06.005
Agirman, G., Yu, K. B., & Hsiao, E. Y. (2021). Signaling inflammation across the gut-brain axis. Science (New York, N.Y.), 374(6571), 1087–1092. https://doi.org/10.1126/science.abi6087
Chen, W., Zhang, S., Wu, J., Ye, T., Wang, S., Wang, P., & Xing, D. (2020). Butyrate-producing bacteria and the gut-heart axis in atherosclerosis. Clinica chimica acta; international journal of clinical chemistry, 507, 236–241. https://doi.org/10.1016/j.cca.2020.04.037
Lizogub, V.G., Kramarova, V.N., Melnychuk, I.O. (2019) The role of gut microbiota changes in the pathogenesis of heart disease. Zaporizkiy medical journal, 21, 5 (116), 672–678. doi: 10.14739 / 2310-1210.2019.5.179462
Chávez-Talavera, O., Tailleux, A., Lefebvre, P., & Staels, B. (2017). Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease. Gastroenterology, 152(7), 1679–1694.e3. https://doi.org/10.1053/j.gastro.2017.01.055
Takiishi, T., Fenero, C. I. M., & Câmara, N. O. S. (2017). Intestinal barrier and gut microbiota: Shaping our immune responses throughout life. Tissue barriers, 5(4), e1373208. https://doi.org/10.1080/21688370.2017.1373208
Li, J. J., Liu, H. H., & Li, S. (2022). Landscape of cardiometabolic risk factors in Chinese population: a narrative review. Cardiovascular diabetology, 21(1), 113. https://doi.org/10.1186/s12933-022-01551-3
Andrikoula, M., & McDowell, I. F. (2008). The contribution of ApoB and ApoA1 measurements to cardiovascular risk assessment. Diabetes, obesity & metabolism, 10(4), 271–278. https://doi.org/10.1111/j.1463-1326.2007.00714.x
Kamstrup, P. R. (2021). Lipoprotein(a) and Cardiovascular Disease. Clinical chemistry, 67(1), 154–166. https://doi.org/10.1093/clinchem/hvaa247
Scheff, SW Fundamental Statistical Principles for the Neurobiologist. A Survival Guide. Lexington: Academic Press;2016.
Mandrekar J. N. (2010). Receiver operating characteristic curve in diagnostic test assessment. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 5(9), 1315–1316. https://doi.org/10.1097/JTO.0b013e3181ec173d
Chen, M., Fang, CY, Guo, JC, et all. (2023) Predictive value of atherogenic index of plasma and atherogenic index of plasma combined with low-density lipoprotein cholesterol for the risk of acute myocardial infarction Front Cardiovasc Med, 10, 1117362. doi: 10.3389/fcvm.2023.1117362. eCollection 2023.
Gawałko, M., Linz, D., & Dobrev, D. (2021). Gut-microbiota derived TMAO: A risk factor, a mediator or a bystander in the pathogenesis of atrial fibrillation? International journal of cardiology. Heart & vasculature, 34, 100818. https://doi.org/10.1016/j.ijcha.2021.100818
Dong, H., Wang, J., Hu, P., & Lu, N. (2023). Association of Apolipoprotein A1, High Density Lipoprotein Cholesterol, and Their Ratio with Inflammatory Marker in Chinese Adults with Coronary Artery Disease. Angiology, 74(8), 765–773. https://doi.org/10.1177/00033197221121002
Wang, J., Gu, X., Yang, J., Wei, Y., & Zhao, Y. (2019). Gut Microbiota Dysbiosis and Increased Plasma LPS and TMAO Levels in Patients With Preeclampsia. Frontiers in cellular and infection microbiology, 9, 409. https://doi.org/10.3389/fcimb.2019.00409
Gao, X., Du, L., Randell, E., Zhang, H., Li, K., & Li, D. (2021). Effect of different phosphatidylcholines on high fat diet-induced insulin resistance in mice. Food & function, 12(4), 1516–1528. https://doi.org/10.1039/d0fo02632h
Zysset-Burri, D. C., Keller, I., Berger, L. E., Neyer, P. J., Steuer, C., Wolf, S., & Zinkernagel, M. S. (2019). Retinal artery occlusion is associated with compositional and functional shifts in the gut microbiome and altered trimethylamine-N-oxide levels. Scientific reports, 9(1), 15303. https://doi.org/10.1038/s41598-019-51698-5
Wieland, A., Frank, D. N., Harnke, B., & Bambha, K. (2015). Systematic review: microbial dysbiosis and nonalcoholic fatty liver disease. Alimentary pharmacology & therapeutics, 42(9), 1051–1063. https://doi.org/10.1111/apt.13376
Ke, J., An, Y., Cao, B., Lang, J., Wu, N., & Zhao, D. (2020). Orlistat-Induced Gut Microbiota Modification in Obese Mice. Evidence-based complementary and alternative medicine: eCAM, 2020, 9818349. https://doi.org/10.1155/2020/9818349
Guo, G., Wu, Y., Liu, Y., Wang, Z., Xu, G., Wang, X., Liang, F., Lai, W., Xiao, X., Zhu, Q., & Zhong, S. (2023). Exploring the causal effects of the gut microbiome on serum lipid levels: A two-sample Mendelian randomization analysis. Frontiers in microbiology, 14, 1113334. https://doi.org/10.3389/fmicb.2023.1113334
Lei, W., Cheng, Y., Gao, J., Liu, X., Shao, L., Kong, Q., Zheng, N., Ling, Z., & Hu, W. (2023). Akkermansia muciniphila in neuropsychiatric disorders: friend or foe? Frontiers in cellular and infection microbiology, 13, 1224155. https://doi.org/10.3389/fcimb.2023.1224155
Luo, Y., Zhang, Y., Han, X., Yuan, Y., Zhou, Y., Gao, Y., Yu, H., Zhang, J., Shi, Y., Duan, Y., Zhao, X., Yan, S., Hao, H., Dai, C., Zhao, S., Shi, J., Li, W., Zhang, S., Xu, W., Fang, N., Li, Y. (2022). Akkermansia muciniphila prevents cold-related atrial fibrillation in rats by modulation of TMAO induced cardiac pyroptosis. EBioMedicine, 82, 104087. https://doi.org/10.1016/j.ebiom.2022.104087
Fang, C., Zuo, K., Zhang, W., Zhong, J., Li, J., Xu, L., & Yang, X. (2022). Association between Gut Microbiota Dysbiosis and the CHA2DS2-VASc Score in Atrial Fibrillation Patients. International journal of clinical practice, 7942605. https://doi.org/10.1155/2022/7942605
Xu, W., Yu, J., Yang, Y., Li, Z., Zhang, Y., Zhang, F., Wang, Q., Xie, Y., Zhao, B., & Wu, C. (2023). Strain-level screening of human gut microbes identifies Blautia producta as a new anti-hyperlipidemic probiotic. Gut microbes, 15(1), 2228045. https://doi.org/10.1080/19490976.2023.2228045
Costa, S. K., Antosca, K., Beekman, C. N., Peterson, R. L., Penumutchu, S., & Belenky, P. (2023). Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis. Microbiology spectrum, e0237623. Advance online publication. https://doi.org/10.1128/spectrum.02376-23
McMillan, A. S., Foley, M. H., Perkins, C. E., & Theriot, C. M. (2023). Loss of Bacteroides thetaiotaomicron bile acid altering enzymes impact bacterial fitness and the global metabolic transcriptome. bioRxiv : the preprint server for biology, 2023.06.27.546749. https://doi.org/10.1101/2023.06.27.546749
González-Morelo, K. J., Vega-Sagardía, M., & Garrido, D. (2020). Molecular Insights Into O-Linked Glycan Utilization by Gut Microbes. Frontiers in microbiology, 11, 591568. https://doi.org/10.3389/fmicb.2020.591568
Al-Kaisey, A. M., Figgett, W., Hawson, J., Mackay, F., Joseph, S. A., & Kalman, J. M. (2023). Gut Microbiota and Atrial Fibrillation: Pathogenesis, Mechanisms and Therapies. Arrhythmia & electrophysiology review, 12, e14. https://doi.org/10.15420/aer.2022.33
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.